Skip to main content
. 2012 Sep;67(9):1093–1099. doi: 10.6061/clinics/2012(09)18

Figure 1.

Figure 1

Combined treatment with sorafenib and VK2 inhibits HCC cell growth. (A) Growth inhibition of HepG2 cells by sorafenib, VK2 or the two in combination. (B) The growth-inhibitory effects of VK2 in addition to various sorafenib concentrations. (C) Growth inhibition of Hep3B and HuH7 cells by sorafenib, VK2 or the two in combination. SF: sorafenib. Each point represents the mean±SD of three independent experiments. * p<0.05 vs. control or single-agent treatment.